Stockscreener 앱 받기
1.30
3.70%
-0.05
시간 외 거래:
1.31
0.01
+0.77%
전일 마감가:
$1.35
열려 있는:
$1.35
하루 거래량:
40,279
Relative Volume:
1.27
시가총액:
$8.02M
수익:
$93.76M
순이익/손실:
$-13.68M
주가수익비율:
-0.4943
EPS:
-2.63
순현금흐름:
$8.77M
1주 성능:
-6.14%
1개월 성능:
-23.53%
6개월 성능:
-46.72%
1년 성능:
-55.63%
1일 변동 폭
$1.30
$1.36
1주일 범위
$1.30
$1.4492
52주 변동 폭
$1.30
$3.4475
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
AYTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
1.30 | 8.02M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
165.31 | 74.02B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.90B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.23B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.57 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
AYTU stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
AYTU stock touches 52-week low at $1.3 amid market challenges - Investing.com UK
Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 - ACCESS Newswire
Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings - MSN
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - ACCESS Newswire
Aytu BioPharma’s Imminent Breakthrough: Can It Reach Profitability? - Mi Valle
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance
Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Stro - GuruFocus.com
Aytu BioScience Earnings Call: Growth Amid Challenges - TipRanks
Denver biotech cuts $500K check when it parted ways with its CFO - The Business Journals
Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... By GuruFocus - Investing.com Canada
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Reports Strong Q2 Earnings Growth - TipRanks
Aytu BioPharma Inc. (AYTU) reports earnings - Quartz
AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView
Aytu BioPharma Reports Fiscal 2025 Second Quarter Results - TradingView
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results - ACCESS Newswire
Aytu BioPharma Turns Profitable: Key Portfolio Growth Drives Q2 Transformation - StockTitan
Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - Galveston County Daily News
Aytu BioPharma Earnings Alert: Key Financial Results Coming February 12What to Watch - StockTitan
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 - ACCESS Newswire
Aytu BioPharma to Present at LD Micro Main Event XVI Conference - ACCESS Newswire
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 - ACCESS Newswire
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - ACCESS Newswire
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso - ACCESS Newswire
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - ACCESS Newswire
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - ACCESS Newswire
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - ACCESS Newswire
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - ACCESS Newswire
Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St
Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World
An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com
Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World
Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance
Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan
Aytu BioPharma Disclosure Notification - AccessWire
Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance
Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan
Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
1.31%
자본화:
|
볼륨(24시간):